Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer
Sponsor: BioNumerik Pharmaceuticals, Inc.
This PHASE3 trial investigates Ovarian Cancer and is currently completed. BioNumerik Pharmaceuticals, Inc. leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — Apr 2020 [monthly]
Completed PHASE3
-
Nov 2018 — Aug 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioNumerik Pharmaceuticals, Inc.
- Crown Bioscience
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Birobidzhan, Russia , Bucharest, Romania , Budapest, Hungary , Cluj-Napoca, Romania , Craiova, Romania , Elblag, Poland , Engel's, Russia , Győr, Hungary , Iași, Romania and 33 more locations